Our technologies are based on tunable and biodegradable nanoparticles and small molecules ligands. They’re advancing our fundamental understanding of transcytosis at the intestine-blood barrier, paving the way for effective delivery of poorly bioavailable peptides, proteins, and other small molecules.

Peroral Biosciences, Inc., ​

An early-stage biotech startup based in San Diego, CA, is developing the next generation of peroral dosage forms of poorly bioavailable peptides, proteins, and other small molecules.